CN1093126C - 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 - Google Patents

合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 Download PDF

Info

Publication number
CN1093126C
CN1093126C CN97195996A CN97195996A CN1093126C CN 1093126 C CN1093126 C CN 1093126C CN 97195996 A CN97195996 A CN 97195996A CN 97195996 A CN97195996 A CN 97195996A CN 1093126 C CN1093126 C CN 1093126C
Authority
CN
China
Prior art keywords
acid
compound
formula
acid catalyst
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97195996A
Other languages
English (en)
Chinese (zh)
Other versions
CN1223647A (zh
Inventor
T·E·扎克斯
D·E·布特勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1223647A publication Critical patent/CN1223647A/zh
Application granted granted Critical
Publication of CN1093126C publication Critical patent/CN1093126C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/03Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
CN97195996A 1996-07-29 1997-07-01 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法 Expired - Fee Related CN1093126C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2236996P 1996-07-29 1996-07-29
US60/022,369 1996-07-29

Publications (2)

Publication Number Publication Date
CN1223647A CN1223647A (zh) 1999-07-21
CN1093126C true CN1093126C (zh) 2002-10-23

Family

ID=21809241

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97195996A Expired - Fee Related CN1093126C (zh) 1996-07-29 1997-07-01 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法

Country Status (17)

Country Link
US (1) US5998633A (cg-RX-API-DMAC7.html)
EP (1) EP0915866B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000515882A (cg-RX-API-DMAC7.html)
KR (1) KR100447370B1 (cg-RX-API-DMAC7.html)
CN (1) CN1093126C (cg-RX-API-DMAC7.html)
AT (1) ATE215078T1 (cg-RX-API-DMAC7.html)
AU (1) AU3515497A (cg-RX-API-DMAC7.html)
CO (1) CO4950542A1 (cg-RX-API-DMAC7.html)
DE (1) DE69711391T2 (cg-RX-API-DMAC7.html)
DK (1) DK0915866T3 (cg-RX-API-DMAC7.html)
ES (1) ES2176756T3 (cg-RX-API-DMAC7.html)
HU (1) HU226465B1 (cg-RX-API-DMAC7.html)
IL (1) IL127058A (cg-RX-API-DMAC7.html)
PT (1) PT915866E (cg-RX-API-DMAC7.html)
TR (1) TR199900191T2 (cg-RX-API-DMAC7.html)
WO (1) WO1998004543A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA976705B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1093126C (zh) * 1996-07-29 2002-10-23 沃尼尔·朗伯公司 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法
WO2000005400A1 (en) * 1998-07-24 2000-02-03 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (s)-3,4-dihydroxybutyric acid derivatives
US6713290B2 (en) 1998-07-24 2004-03-30 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
KR100332703B1 (ko) * 1998-07-24 2002-08-27 삼성정밀화학 주식회사 광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
US6235930B1 (en) * 1999-03-31 2001-05-22 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
ATE309985T1 (de) 1999-12-17 2005-12-15 Pfizer Science & Tech Ltd Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
HUP0203798A3 (en) 1999-12-17 2008-10-28 Warner Lambert Res & Dev Ie A process for producing crystalline atorvastatin calcium
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
KR100645665B1 (ko) 2000-07-27 2006-11-13 에스케이 주식회사 (s)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (en) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carboxylic acid salts of beta-alanine esters or -amides
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
JP3965155B2 (ja) 2001-06-29 2007-08-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 結晶型[R−(R*,R*)]−2−(4−フルオロフェニル)−β,δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)(アトロバスタチン)
PL366610A1 (en) * 2001-07-06 2005-02-07 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
KR100598079B1 (ko) * 2002-02-25 2006-07-07 바이오콘 리미티드 신규의 보로네이트 에스테르
GB0211716D0 (en) 2002-05-22 2002-07-03 Phoenix Chemicals Ltd Process
RU2279430C2 (ru) 2002-08-06 2006-07-10 Уорнер-Ламберт Компани Ллс Способ получения фениламида 5-(4-фторфенил)-1-[2-(2r,4r)-4-гидрокси-6-оксотетрагидропиран-2-ил)этил]-2-изопропил-4-фенил-1h-пиррол-3-карбоновой кислоты
CA2499655A1 (en) * 2002-09-18 2004-04-01 Sk Corporation Continuous process for the production of optically pure (s)-.beta.-hydroxy-.gamma.-butyrolactone
EP1625223A4 (en) * 2002-09-20 2009-11-11 Verenium Corp CHEMOENZYMATIC PROCEDURES FOR SYNTHESIS OF STATINES AND STATIN INTERCONNECTIONS
US6713639B1 (en) 2002-10-28 2004-03-30 Council Of Scientific And Industrial Research Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
KR100780984B1 (ko) * 2003-04-14 2007-11-29 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2r,4r)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1h-피롤-3-카르복실산 페닐아미드의 제조 방법
ATE425132T1 (de) * 2003-04-22 2009-03-15 Biocon Ltd Neues verfahren zur stereoselektiven reduktion von beta-ketoestern
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CA2539158A1 (en) * 2003-09-17 2005-03-24 Warner-Lambert Company Llc Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
WO2005068642A2 (en) 2003-10-01 2005-07-28 Board Of Trustees Operating Michigan State University Bacterial synthesis of 1,2,4-butanetriol enantiomers
KR100829268B1 (ko) * 2004-04-16 2008-05-13 화이자 프로덕츠 인코포레이티드 비정질 아토바스타틴 칼슘의 제조 방법
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US7714141B2 (en) * 2005-05-31 2010-05-11 Kowa Co., Ltd. Processes for production of optically active PPAR-activating compounds and intermediates for production thereof
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
US20110165641A1 (en) * 2006-03-31 2011-07-07 The Board Of Trustees Of Michigan State University Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
EP2054518A2 (en) * 2006-07-19 2009-05-06 Board of Trustees of Michigan State University Microbial synthesis of d-1,2,4-butanetriol
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
JP2009256316A (ja) 2008-03-28 2009-11-05 Daicel Chem Ind Ltd β−ヒドロキシ−γ−ブチロラクトンの製造方法
CN101337906B (zh) * 2008-08-15 2012-06-27 河南豫辰精细化工有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN106588689A (zh) * 2016-12-15 2017-04-26 河南豫辰药业股份有限公司 一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
CN112939901B (zh) * 2021-02-09 2023-05-09 中国科学院福建物质结构研究所 一种α-羟基-γ-丁内酯的制备方法
CN114195670B (zh) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 一种阿托伐他汀母核m4的精制方法
CN117447350A (zh) * 2023-10-26 2024-01-26 河南豫辰药业股份有限公司 一种阿托伐他汀m4有机废物综合再利用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292939A (en) * 1991-05-13 1994-03-08 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710688B2 (ja) * 1990-10-09 1998-02-10 鐘淵化学工業株式会社 4―ブロモ―3―ヒドロキシ酪酸エステル誘導体の製造法
JP3351563B2 (ja) * 1992-12-03 2002-11-25 鐘淵化学工業株式会社 3−ヒドロキシ酪酸誘導体の製造法
CN1093126C (zh) * 1996-07-29 2002-10-23 沃尼尔·朗伯公司 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292939A (en) * 1991-05-13 1994-03-08 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof

Also Published As

Publication number Publication date
EP0915866A1 (en) 1999-05-19
US5998633A (en) 1999-12-07
JP2000515882A (ja) 2000-11-28
ES2176756T3 (es) 2002-12-01
CO4950542A1 (es) 2000-09-01
ATE215078T1 (de) 2002-04-15
HK1020728A1 (en) 2000-05-19
DE69711391D1 (de) 2002-05-02
IL127058A (en) 2001-07-24
WO1998004543A1 (en) 1998-02-05
KR20000029648A (ko) 2000-05-25
DE69711391T2 (de) 2002-11-07
IL127058A0 (en) 1999-09-22
TR199900191T2 (xx) 1999-04-21
HUP9904348A3 (en) 2004-03-01
HUP9904348A2 (hu) 2000-04-28
PT915866E (pt) 2002-07-31
DK0915866T3 (da) 2002-06-10
CN1223647A (zh) 1999-07-21
ZA976705B (en) 1998-02-10
EP0915866B1 (en) 2002-03-27
HU226465B1 (en) 2008-12-29
KR100447370B1 (ko) 2004-09-08
AU3515497A (en) 1998-02-20

Similar Documents

Publication Publication Date Title
CN1093126C (zh) 合成被保护的(s)-3,4-二羟基丁酸酯的改进方法
JP3429500B2 (ja) 4−シアノ−3−ヒドロキシ酪酸エステルの製造方法
EP1077212B1 (en) Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
CN1122029C (zh) 制备辛伐他汀的方法
JP3822644B2 (ja) 1,3―ジオキソラン―4―メタノール化合物の製造法
JPH04211075A (ja) アルキレンカーボネートの製造法
JPWO1998011087A1 (ja) 1,3−ジオキソラン−4−メタノール化合物の製造法
WO2003018570A1 (en) Process of lactonization in the preparation of statins
WO2008075165A1 (en) Novel process for the synthesis of [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid or a pharmaceutically acceptable salt thereof
EP0943612B1 (en) Process for producing cyclic carbonic esters
JP3076154B2 (ja) (3r,5s)−3,5,6−トリヒドロキシヘキサン酸誘導体及びその製造方法
JP3303327B2 (ja) 不斉誘起触媒
JPS62289549A (ja) N−(α−アルコキシエチル)−カルボン酸アミドの製造方法
HK1020728B (en) Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
EP1167365B1 (en) Method of producing sesamol formic acid ester and sesamol
RU2214407C2 (ru) Усовершенствованный способ лактонизации при получении статинов
CN1202102C (zh) 2-香豆酮和取代的2-香豆酮的生产方法
JP4598917B2 (ja) ラクトンの製造方法
KR920000953B1 (ko) 광학활성 3, 4-디히드록시 부티르산 유도체의 제조방법
JP3900202B2 (ja) 1,3−ジオキソラン−4−メタノール化合物の製造法
JP4071633B2 (ja) アルキルベンゾイルアクリレートの製造方法
JPH06102636B2 (ja) N―メチル―3,4―ジメトキシフェニルエチルアミンの新規合成方法
CN1732149A (zh) 合成3,3A,6,6A-四氢-2H-环戊烯并[b]呋喃-2-酮的方法
JPH0769960A (ja) 光学活性2−ノルボルナノンの製造方法
JPWO1999057109A1 (ja) 6−シアノメチル−1,3−ジオキサン−4−酢酸誘導体の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Pfizer Pharmaceuticals Limited

Assignor: Vonil Longbow (Warner & Lambert) Pfizer, Inc.

Contract fulfillment period: Contract performance period from January 10, 2006 to January 10, 2009

Contract record no.: Contract filing No. 061000010077

Denomination of invention: Improved methods for the synthesis of protected (S) -3, 4-, two butyric acid esters

Granted publication date: 20021023

Record date: 20060818

LIC Patent licence contract for exploitation submitted for record

Free format text: LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2006.1.10 TO 2009.1.10

Name of requester: PFIZER(WARNER-LAMBERT) PHARMACEUTICAL CO., LTD.

Effective date: 20060818

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021023